TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9514531

Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg daily for 1 year)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (identical capsule)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 7997376

Group type: EXPERIMENTAL
Intervention: 123I-Iomazenil SPECT
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Surgical resection of the epileptogenic area
Number of subjects: 33

Group type: COMPARATOR
Intervention: 99mTc-HMPAO SPECT
Number of subjects: 33
Study: 3288680

Group type: EXPERIMENTAL
Intervention: Björk‐Shiley prosthesis
Number of subjects: 575

Group type: COMPARATOR
Intervention: Hancock heterograft
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Both prostheses
Number of subjects: 575
Study: 29052252

Group type: EXPERIMENTAL
Intervention: Social exclusion manipulation (Study 1)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Violent video game playing (Study 2)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Nonviolent video game playing (Study 2)
Number of subjects: 234
Study: 27167769

Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal Saline (Control)
Number of subjects: 120
Study: 24716675

Group type: EXPERIMENTAL
Intervention: Atypical subgroup with impulsive traits
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Typically inhibited subgroup
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Treatment outcome
Number of subjects: 84
Study: 23086295

Group type: EXPERIMENTAL
Intervention: vibroX
Number of subjects: 8

Group type: COMPARATOR
Intervention: RES
Number of subjects: 8
Study: 20179632

Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 397

Group type: COMPARATOR
Intervention: Viscocanalostomy
Number of subjects: 397
Study: 17631948

Group type: EXPERIMENTAL
Intervention: Cangrelor IV bolus (30 microg/kg) and a 2-hour infusion (4 microg/kg/min) with 600 mg clopidogrel loading dose
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cangrelor bolus and a 1-hour infusion with 600 mg clopidogrel loading dose
Number of subjects: 10
Study: 16777855

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 or 400 mg/day
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sustained-release paracetamol 1330 mg three times a day
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 59
Study: 14983653

Group type: EXPERIMENTAL
Intervention: Budesonide (1 mg/2 ml) diluted with 2 ml isotonic sodium chloride
Number of subjects: 73

Group type: COMPARATOR
Intervention: Isotonic sodium chloride (4 ml)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Terbutaline (5 mg/2 ml) diluted with 2 ml isotonic sodium chloride
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Budesonide (1 mg/2 ml) and terbutaline (5 mg/2 ml)
Number of subjects: 73
Study: 10741293

Group type: EXPERIMENTAL
Intervention: Amenorrhoea
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Irregular menstruation
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Menstruation status after chemotherapy
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: FSH level
Number of subjects: 126
Study: 9083827

Group type: EXPERIMENTAL
Intervention: Intranasal administration of 6 mg heroin hydrochloride
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intranasal administration of 12 mg heroin hydrochloride
Number of subjects: 4

Group type: COMPARATOR
Intervention: Intramuscular administration of 6 mg heroin hydrochloride
Number of subjects: 4
Study: 8366922

Group type: EXPERIMENTAL
Intervention: Intensive therapy (external insulin pump or three or more daily insulin injections with frequent blood glucose monitoring)
Number of subjects: 1441

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Conventional therapy (one or two daily insulin injections)
Number of subjects: 1441
Study: 3780290

Group type: EXPERIMENTAL
Intervention: ergoloid mesylates (1.5 mg 3-times daily)
Number of subjects: 148

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 148
Study: 31624333

Group type: EXPERIMENTAL
Intervention: Creatine treatment
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Valproic acid treatment
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: UNC13A genotype
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: C9orf72 repeat‐expansion carriers
Number of subjects: 338
Study: 29615078

Group type: EXPERIMENTAL
Intervention: Early colonoscopy (performed within 24 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Elective colonoscopy (performed between 24 and 96 h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early colonoscopy
Number of subjects: 0
Study: 27906937

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transversus abdominis plane block (USG-TAPB) with local anesthetic
Number of subjects: 96

Group type: COMPARATOR
Intervention: Ultrasound-guided transversus abdominis plane block (USG-TAPB) with saline
Number of subjects: 96
Study: 24988203

Group type: EXPERIMENTAL
Intervention: Difaprost®
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (no additional therapy)
Number of subjects: 36
Study: 22820908

Group type: EXPERIMENTAL
Intervention: ilaprazole (5 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: clarithromycin (500 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: triple therapy (ilaprazole 5 mg, clarithromycin 500 mg, amoxicillin 1 g)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ilaprazole sulfone
Number of subjects: 12
Study: 20523253

Group type: EXPERIMENTAL
Intervention: diazepam 10 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: diazepam 10 mg plus clonidine 0.15 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: midazolam 15 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: midazolam plus clonidine 0.15 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: midazolam (with or without clonidine)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: midazolam plus clonidine
Number of subjects: 70
Study: 18477263

Group type: EXPERIMENTAL
Intervention: EXU 3 mg with no passive smoke exposure
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: EXU 3 mg after passive smoke exposure (atmospheric nicotine levels 75-125 mug m(‐3) for 2 h)
Number of subjects: 27
Study: 16165272

Group type: EXPERIMENTAL
Intervention: ApoE epsilon4 carriers with MCI
Number of subjects: 31

Group type: COMPARATOR
Intervention: Non-carriers with MCI
Number of subjects: 31

Group type: COMPARATOR
Intervention: AD patients
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 31
Study: 12525530

Group type: EXPERIMENTAL
Intervention: NIH physician‐based smoking intervention
Number of subjects: 432

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 432
Study: 10858488

Group type: EXPERIMENTAL
Intervention: lovastatin (20-40 mg/day, titrated to achieve LDL-cholesterol target of < or =110 mg/dL)
Number of subjects: 6605

Group type: EXPERIMENTAL
Intervention: lovastatin
Number of subjects: 6605
Study: 8669564

Group type: EXPERIMENTAL
Intervention: Epidural blockade with bupivacaine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no epidural blockade)
Number of subjects: 31
Study: 1320987

Group type: EXPERIMENTAL
Intervention: Inhaled nedocromil 4 mg q.i.d. for 8 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 6469434

Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: nifedipine
Number of subjects: 30
Study: 31365799

Group type: EXPERIMENTAL
Intervention: Immediate transfusion with 20 ml or 30 ml of whole-blood equivalent per kilogram of body weight
Number of subjects: 1565

Group type: COMPARATOR
Intervention: Control group (no immediate transfusion, transfusion triggered by clinical severity or hemoglobin drop)
Number of subjects: 1565

Group type: EXPERIMENTAL
Intervention: Immediate transfusion
Number of subjects: 1565

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1565
Study: 30445919

Group type: EXPERIMENTAL
Intervention: Frailty phenotype assessment
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Frailty phenotype assessment with missing data counted as meeting frailty criterion
Number of subjects: 235
Study: 27780331

Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg/day)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study: 24700254

Group type: EXPERIMENTAL
Intervention: Intranasal PH94B
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo aerosol spray
Number of subjects: 91
Study: 23138167

Group type: EXPERIMENTAL
Intervention: Cetuximab 500 mg/m2 every 2 weeks (Group A)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cetuximab 750 mg/m2 every 2 weeks (Group B)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 61
Study: 20363366

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol reinduction (400 mg at weeks 0, 2, and 4)
Number of subjects: 124
Study: 17933836

Group type: EXPERIMENTAL
Intervention: Ventilation during bypass (VB)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Non-ventilation during bypass (NVB)
Number of subjects: 23
Study: 15507489

Group type: EXPERIMENTAL
Intervention: Health improvement services targeting mid-life individuals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combining free health checks with financial advice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opportunities to engage in social activities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gains in knowledge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Validation of existing knowledge
Number of subjects: 0
Study: 11948381

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone 400 microg/d
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone 800 microg/d
Number of subjects: 78

Group type: COMPARATOR
Intervention: Intravenous dexamethasone
Number of subjects: 78
Study: 9465753

Group type: EXPERIMENTAL
Intervention: 10% pentastarch solution (PS)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Isotonic 0.9% NaCl solution (IS)
Number of subjects: 23
Study: 7629954

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (25 mg daily)
Number of subjects: 580

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 580
Study: 2664372

Group type: EXPERIMENTAL
Intervention: FAMTX protocol (high dose methotrexate and 5-fluorouracil combined with adriamycin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: FAM protocol (5-fluorouracil, adriamycin and mitomycin)
Number of subjects: 0
Study: 786772

Group type: EXPERIMENTAL
Intervention: Sodium amylosulfate (Depepsen)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 31151306

Group type: EXPERIMENTAL
Intervention: IBD98-M 0.8 g/day
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: IBD98-M 1.2 g/day
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 28240020

Group type: EXPERIMENTAL
Intervention: Random Survival Forest (RSF) approach
Number of subjects: 128
Study: 26342188

Group type: EXPERIMENTAL
Intervention: SPA-TLH
Number of subjects: 60

Group type: COMPARATOR
Intervention: MPA-TLH
Number of subjects: 60
Study: 23524476

Group type: EXPERIMENTAL
Intervention: Distraction Group (VOAD)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Distraction-Free Group
Number of subjects: 32
Study: 18256913

Group type: EXPERIMENTAL
Intervention: Supplementary support during pregnancy
Number of subjects: 1403
Study: 19340730

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 150

Group type: COMPARATOR
Intervention: Midazolam plus meperidine
Number of subjects: 150
Study: 16506872

Group type: EXPERIMENTAL
Intervention: High-grade mobilization techniques (HGMT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low-grade mobilization techniques (LGMT)
Number of subjects: 100
Study: 10392645

Group type: EXPERIMENTAL
Intervention: Qualified physiotherapy (QPT) - additional treatment from a qualified physiotherapist
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Assistant physiotherapy (APT) - additional treatment from a trained supervised assistant
Number of subjects: 282

Group type: COMPARATOR
Intervention: Routine physiotherapy (RPT) - no additional physiotherapy
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Additional treatment (QPT and APT)
Number of subjects: 282
Study: 8675249

Group type: EXPERIMENTAL
Intervention: Nifedipine plus diltiazem (180 mg/d)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nifedipine plus verapamil (180 mg/d)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nifedipine alone (30 mg/d)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nifedipine plus diltiazem
Number of subjects: 16
Study: 1812599

Group type: EXPERIMENTAL
Intervention: Amodiaquine
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Pyrimethamine-sulfadoxine (FansidarR)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Pyrimethamine-sulfalene (MetakelfinR)
Number of subjects: 401
Study: 6417027

Group type: EXPERIMENTAL
Intervention: Isolation and decontamination procedures in laminar air flow rooms (90 patients)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Prophylactic granulocyte transfusion from a single family member (92 patients)
Number of subjects: 182
Study: 31076930

Group type: COMPARATOR
Intervention: D1 lymphadenectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D2 lymphadenectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: D3 lymphadenectomy
Number of subjects: 0
Study: 29649377

Group type: EXPERIMENTAL
Intervention: Physical activity-based lifestyle intervention (3 months)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nonintervention group (control)
Number of subjects: 21
Study: 26329382

Group type: EXPERIMENTAL
Intervention: Modafinil (MOD) 200 mg daily for 4 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 24797449

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA, 20 min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (2 mA, 20 min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS (2 mA, 20 min)
Number of subjects: 0
Study: 22408124

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 20152611

Group type: EXPERIMENTAL
Intervention: AcrySof ReSTOR SA60D3 multifocal IOL
Number of subjects: 161

Group type: COMPARATOR
Intervention: AcrySof SA60AT single‐piece monofocal IOL
Number of subjects: 161
Study: 17633129

Group type: EXPERIMENTAL
Intervention: Mini bypass system
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional system
Number of subjects: 60
Study: 16040091

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 100
Study: 12183724

Group type: EXPERIMENTAL
Intervention: Serum pancreatic trypsinogen and isoamylase measurements in patients with SDS
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: CART analysis applied to patients with SDS
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control patients (not specified intervention)
Number of subjects: 164
Study: 10448444

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Moclobemide plus clinical management
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Moclobemide plus CBT
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo plus CBT
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo plus clinical management
Number of subjects: 55
Study: 7799065

Group type: EXPERIMENTAL
Intervention: 111In‐DTPA‐D‐Phe‐1‐octreotide
Number of subjects: 41
Study: 2139791

Group type: EXPERIMENTAL
Intervention: Unfilled light-cured resin
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Filled light-cured resin
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Light-cured resins (both types)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Chemically-cured material (control)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Gel form etchant
Number of subjects: 186
Study: 30612116

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 140
Study: 28759307

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) at 25 mmHg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) at 35 mmHg
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) at 45 mmHg
Number of subjects: 45
Study: 26479271

Group type: EXPERIMENTAL
Intervention: Wire-guided endoscopic snare papillectomy (WP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional endoscopic snare papillectomy (CP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional endoscopic snare papillectomy (CP) without stents
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional endoscopic snare papillectomy (CP) with stents
Number of subjects: 45
Study: 25131843

Group type: EXPERIMENTAL
Intervention: Passive polarizing 3D display
Number of subjects: 20
Study: 22381043

Group type: EXPERIMENTAL
Intervention: Ritonavir (300 mg twice daily for 3 days)
Number of subjects: 14
Study: 20461335

Group type: EXPERIMENTAL
Intervention: Standardized task‐oriented therapy with botulinum toxin injections
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standardized task‐oriented therapy without botulinum toxin injections
Number of subjects: 20
Study: 17636152

Group type: EXPERIMENTAL
Intervention: Mental Stress (MS)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 58
Study: 15608311

Group type: EXPERIMENTAL
Intervention: Combination of DMARDs with prednisolone
Number of subjects: 195

Group type: COMPARATOR
Intervention: Single DMARD
Number of subjects: 195
Study: 12379183

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided core biopsy with a spring-loaded device
Number of subjects: 54
Study: 9920517

Group type: EXPERIMENTAL
Intervention: ALA-rich diet (n=15)
Number of subjects: 29

Group type: COMPARATOR
Intervention: LA-rich diet (n=14)
Number of subjects: 29
Study: 7485304

Group type: EXPERIMENTAL
Intervention: Active device (data revealed)
Number of subjects: 1355

Group type: COMPARATOR
Intervention: Sham device (data concealed)
Number of subjects: 1355
Study: 2078483

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with cyclophosphamide, methotrexate, 5‐fluorouracil, and low‐dose prednisone (CMFp)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Surgical oophorectomy followed by CMFp (Ox + CMFp)
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: CMFp in ER+ tumors
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: CMFp in ER- tumors
Number of subjects: 327
Study: 380909

Group type: EXPERIMENTAL
Intervention: Amineptine (200 mg per day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Trimipramine (75 mg per day)
Number of subjects: 50
Study: 31282037

Group type: EXPERIMENTAL
Intervention: Anesthetic cream applied after cryotherapy treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cryotherapy treatment without anesthetic cream
Number of subjects: 0
Study: 28402353

Group type: EXPERIMENTAL
Intervention: Connective tissue graft
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guided bone regeneration
Number of subjects: 0
Study: 25906791

Group type: EXPERIMENTAL
Intervention: Otago Exercise Programme (OEP)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Falls Exercise Management (FaME)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 319
Study: 22350098

Group type: EXPERIMENTAL
Intervention: Structured interactive group education program
Number of subjects: 150

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 150
Study: 21817043

Group type: EXPERIMENTAL
Intervention: Updating training for 5 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 0
Study: 19350376

Group type: EXPERIMENTAL
Intervention: Therapeutic horseback riding (12 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 34
Study: 17541571

Group type: EXPERIMENTAL
Intervention: 200 mg oral M6G
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 50 mg oral M6G
Number of subjects: 8

Group type: COMPARATOR
Intervention: 30 mg oral morphine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Paracetamol and sulfasalazine coadministered with M6G
Number of subjects: 8
Study: 15579192

Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogens (CEE) 0.625 mg daily + Desogestrel (DG) 75 microg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogens (CEE) 0.625 mg daily + Medroxyprogesterone (MP) 10 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Conjugated equine oestrogens (CEE) 0.625 mg daily + Norethisterone (NE) 1 mg
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conjugated equine oestrogens (CEE) 0.625 mg daily
Number of subjects: 34
Study: 11764019

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg methylphenidate (MPH)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study: 9757170

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/d, increased to 100 mg/d if uncontrolled after 6 weeks
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/d + Hydrochlorothiazide 12.5 mg/d if uncontrolled after 6 weeks
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/d, increased to 10 mg/d if uncontrolled after 6 weeks
Number of subjects: 302

Group type: COMPARATOR
Intervention: Losartan 50 mg/d
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 302
Study: 9050473

Group type: EXPERIMENTAL
Intervention: Laparoscopic linear salpingotomy with hCG dynamics analysis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laparoscopic linear salpingotomy (control group)
Number of subjects: 60
Study: 3346634

Group type: EXPERIMENTAL
Intervention: Experimental group (home visits)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (office-based care)
Number of subjects: 198